1The diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes[ J]. N Engl J Med,2005 ;353:2643-53.
2Davies M, Storms F, Shutler S, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes[ J]. Diabetes Care,2005; 28:1282-8.
3Chase HP,Lockspeiser T,Peery B,et al. The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin Levels and severe hypoglycemia in type 1 diabetes[ J]. Diabetes Care ,2001 ; 24:430-4.
4Mc Keage K,Goa KL. Insulin glargine:are view of it's therapeu use as along-acting agent for the management of type land 2 diabetes mellitus [J]. Drugs,2001 ;61 ( 11 ) :1599-624.
7Rosenstock J,Schwartz SL,Clark CM,et al. Basal insulin therpy in type 2 diabetes:28-week comparison of insulin glargine (HOE901) and NPH insulin[ J]. Diabetes Care,2001 ;24(4) :631-6.
8Bolli GB,Owen DR. Insuling largine[J]. Lancet,2000;356(9228) :443-5.
二级参考文献13
1[1]Pelkonen R,KoiuistoV,Mustajoki P. Comparison of insulin regimens in the therapy of type 1 diabetes. Acta Ehdocrinol Suppl Copenh,1985,272:49-55.
2[2]Jennings Am, Lewis KS, Mundoch S, et al. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type 2 diabetic Patients poorly controlled With sulfonylureas. Diabetes Care, 1991,14:738.
3[3]Schiffens T. Quality of lift with intensive insulin therapy: a Prospective Comparison of insulin pen and Pump. Psychother Psychosom Med Psychol,1997,47(7):249-254.
4[4]Boland EA,Grey M,Oesterle A,et al. Continuous subcutaneous insulin infusion .A new way to lower risk of severe hypoglycemia , improve Metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care,1999,22(11):1 779-1 784.
5[5]Herman WH,Eastman RC .The effects of treatment on the direct costs of diabetes .Diabetes Care,1998,21 (Suppl.3):C19-24.
6Riddle MC,Rosenstock J,Gerich J.Insulin Glargine 4002 Study Investigators.The treat-to-target trial:randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients[J].Diabetes Care,2003; 26(11):3 080-3 086.
7HOE 901/3002 Study Group.Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes[J].Diabetes Care,2000; 23(8):1 130-1 136
8UKPDS Study Group.Stratton IM,Adler AI,Neil HAW,Matthews DR,Manley SE,Cull CA,Hadden D,Turner RC,Holman RR.Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes:prospective observational study (UKPDS 35) [J].BMJ,20
9Wright A,Burden ACF,Paisey RB.Sulfonylurea Inadequacy:Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57)[J].Diabetes Care,2002; 25(2):330-336
10Turner RC,Cull CA,Frighi V,Holman RR.Glycemic control with diet,sulfonylurea,metformin,or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies (UKPDS 49).UK Prospective Diabetes Study (UKPDS) Group[J].JAMA,1999;
